Repositioning Candidate Details
| Candidate ID: | R0699 |
| Source ID: | DB05095 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Cimicoxib |
| Synonyms: | Cimicoxib |
| Molecular Formula: | C16H13ClFN3O3S |
| SMILES: | COC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O |
| Structure: |
|
| DrugBank Description: | Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. |
| CAS Number: | 265114-23-6 |
| Molecular Weight: | 381.809 |
| DrugBank Indication: | Investigated for use/treatment in depression. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Depression and schizophrenia are inflammatory diseases. Increased levels of pro-inflammatory cytokines and prostaglandin E (PGE) have repeatedly been described in major depression. COX-2 inhibitors inhibit production of both. Cimicoxib is a selective COX-2 inhibitor. The mechanism by which some COX-2 inhibitors work in depression could be linked to their anti-inflammatory mechanisms. |
| Targets: | Prostaglandin G/H synthase 2 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|